Pathfinder Cell Therapy, Inc. (PFND)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2014 | 6.04 Million USD | 28.54% |
| 2013 | 4.7 Million USD | 46.74% |
| 2012 | 3.2 Million USD | 137.38% |
| 2011 | 1.35 Million USD | 20.84% |
| 2010 | 1.11 Million USD | 194.99% |
| 2009 | 379 Thousand USD | -11.45% |
| 2008 | 428 Thousand USD | -23.02% |
| 2007 | 556 Thousand USD | -34.67% |
| 2006 | 851 Thousand USD | -10.98% |
| 2005 | 956 Thousand USD | 21.94% |
| 2004 | 784 Thousand USD | -21.29% |
| 2003 | 996 Thousand USD | -12.94% |
| 2002 | 1.14 Million USD | -36.09% |
| 2001 | 1.79 Million USD | 1.42% |
| 2000 | 1.76 Million USD | -1.34% |
| 1999 | 1.78 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2015 Q3 | 6.76 Million USD | 4.3% |
| 2015 Q1 | 6.3 Million USD | 4.23% |
| 2015 Q2 | 6.49 Million USD | 2.93% |
| 2014 Q3 | 5.72 Million USD | 5.17% |
| 2014 Q4 | 6.04 Million USD | 5.75% |
| 2014 Q1 | 5.17 Million USD | 10.01% |
| 2014 FY | 6.04 Million USD | 28.54% |
| 2014 Q2 | 5.43 Million USD | 5.06% |
| 2013 Q2 | 3.88 Million USD | 3.52% |
| 2013 Q1 | 3.74 Million USD | 16.87% |
| 2013 Q3 | 4.29 Million USD | 10.75% |
| 2013 Q4 | 4.7 Million USD | 9.52% |
| 2013 FY | 4.7 Million USD | 46.74% |
| 2012 Q4 | 3.2 Million USD | 17.77% |
| 2012 Q2 | 2.32 Million USD | 35.27% |
| 2012 FY | 3.2 Million USD | 137.38% |
| 2012 Q1 | 1.71 Million USD | 27.17% |
| 2012 Q3 | 2.72 Million USD | 17.17% |
| 2011 Q3 | 2.22 Million USD | 16.65% |
| 2011 Q2 | 1.91 Million USD | 22.91% |
| 2011 Q1 | 1.55 Million USD | 39.0% |
| 2011 FY | 1.35 Million USD | 20.84% |
| 2011 Q4 | 1.35 Million USD | -39.36% |
| 2010 Q2 | 484 Thousand USD | 3.86% |
| 2010 FY | 1.11 Million USD | 194.99% |
| 2010 Q4 | 1.11 Million USD | 67.87% |
| 2010 Q1 | 466 Thousand USD | 22.96% |
| 2010 Q3 | 666 Thousand USD | 37.6% |
| 2009 Q2 | 340 Thousand USD | -26.25% |
| 2009 Q1 | 461 Thousand USD | 7.71% |
| 2009 Q3 | 327 Thousand USD | -3.82% |
| 2009 FY | 379 Thousand USD | -11.45% |
| 2009 Q4 | 379 Thousand USD | 15.9% |
| 2008 FY | 428 Thousand USD | -23.02% |
| 2008 Q2 | 466 Thousand USD | -36.16% |
| 2008 Q1 | 730 Thousand USD | 31.29% |
| 2008 Q4 | 428 Thousand USD | -2.95% |
| 2008 Q3 | 441 Thousand USD | -5.36% |
| 2007 FY | 556 Thousand USD | -34.67% |
| 2007 Q2 | 462 Thousand USD | -41.52% |
| 2007 Q4 | 556 Thousand USD | -9.59% |
| 2007 Q1 | 790 Thousand USD | -7.17% |
| 2007 Q3 | 615 Thousand USD | 33.12% |
| 2006 Q2 | 716 Thousand USD | -28.83% |
| 2006 Q4 | 851 Thousand USD | 26.64% |
| 2006 FY | 851 Thousand USD | -10.98% |
| 2006 Q1 | 1 Million USD | 5.23% |
| 2006 Q3 | 672 Thousand USD | -6.15% |
| 2005 Q2 | 725 Thousand USD | 2.98% |
| 2005 FY | 956 Thousand USD | 21.94% |
| 2005 Q4 | 956 Thousand USD | 23.67% |
| 2005 Q3 | 773 Thousand USD | 6.62% |
| 2005 Q1 | 704 Thousand USD | -10.2% |
| 2004 Q4 | 784 Thousand USD | -0.63% |
| 2004 FY | 784 Thousand USD | -21.29% |
| 2004 Q3 | 789 Thousand USD | -14.98% |
| 2004 Q2 | 928 Thousand USD | 12.35% |
| 2004 Q1 | 826 Thousand USD | -17.07% |
| 2003 Q3 | 1.2 Million USD | -4.68% |
| 2003 Q1 | 1.15 Million USD | 0.52% |
| 2003 FY | 996 Thousand USD | -12.94% |
| 2003 Q4 | 996 Thousand USD | -17.14% |
| 2003 Q2 | 1.26 Million USD | 9.65% |
| 2002 Q4 | 1.14 Million USD | 15.91% |
| 2002 FY | 1.14 Million USD | -36.09% |
| 2002 Q1 | 1.02 Million USD | -42.51% |
| 2002 Q2 | 992 Thousand USD | -3.6% |
| 2002 Q3 | 987 Thousand USD | -0.5% |
| 2001 FY | 1.79 Million USD | 1.42% |
| 2001 Q4 | 1.79 Million USD | -1.49% |
| 2001 Q2 | 1.71 Million USD | -0.64% |
| 2001 Q1 | 1.72 Million USD | -2.15% |
| 2001 Q3 | 1.81 Million USD | 5.89% |
| 2000 Q4 | 1.76 Million USD | 12.21% |
| 2000 Q3 | 1.57 Million USD | 1.88% |
| 2000 FY | 1.76 Million USD | -1.34% |
| 2000 Q1 | 1.63 Million USD | 0.0% |
| 2000 Q2 | 1.54 Million USD | -5.28% |
| 1999 FY | 1.78 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -21950.086% |
| Arch Therapeutics, Inc. | 9.46 Million USD | 36.097% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 91.653% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -647.904% |
| Rebus Holdings, Inc. | 5.24 Million USD | -15.395% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 89.75% |
| Qrons Inc. | 1.48 Million USD | -306.324% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 1.22 Million USD | -393.307% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 91.926% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -13433.65% |
| Skye Bioscience, Inc. | 14.07 Million USD | 57.015% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 88.652% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | 36.871% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -1334.881% |
| SQZ Biotechnologies Company | 50.03 Million USD | 87.911% |
| Intellipharmaceutics International Inc. | 12 Million USD | 49.628% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -57.059% |
| Mesoblast Limited | 188.44 Million USD | 96.79% |
| Marizyme, Inc. | 26.67 Million USD | 77.324% |
| Genus plc | 485 Million USD | 98.753% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | -3.532% |
| Pharming Group N.V. | 244.07 Million USD | 97.522% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -200.926% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -140.39% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -59.184% |
| ContraFect Corporation | 32.53 Million USD | 81.405% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -205.303% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -58.034% |
| IMV Inc. | 37.93 Million USD | 84.053% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | 48.642% |
| MultiCell Technologies, Inc. | 1617.67 USD | -373832.879% |
| ONE Bio Corp. | 27.49 Million USD | 78.0% |
| Accustem Sciences Inc. | 1.07 Million USD | -460.488% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 92.186% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | -185.995% |
| Q BioMed Inc. | 8.13 Million USD | 25.623% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 92.706% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | -17.547% |
| Biomind Labs Inc. | 1.49 Million USD | -303.64% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 94.905% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | 33.103% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 67.131% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -321.868% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -4157.011% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -2907.717% |
| Curative Biotechnology, Inc. | 5.74 Million USD | -5.277% |
| GB Sciences, Inc. | 5.41 Million USD | -11.655% |
| Alpha Cognition Inc. | 7.16 Million USD | 15.573% |
| HST Global, Inc. | 593.59 Thousand USD | -919.048% |
| CSL Limited | 18.62 Billion USD | 99.968% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -380.387% |
| Halberd Corporation | 728.71 Thousand USD | -730.087% |
| Enzolytics Inc. | 365.26 Million USD | 98.344% |
| Agentix Corp. | 2.51 Million USD | -140.943% |
| Resverlogix Corp. | 67.39 Million USD | 91.025% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -621.208% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 98.641% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -252.917% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 75.556% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 49.181% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -65.04% |
| AVAX Technologies, Inc. | 3.99 Million USD | -51.462% |
| Zenith Capital Corp. | 27.56 Thousand USD | -21841.311% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.544% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -2434.632% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -61.985% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -788.469% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -123.075% |
| Kadimastem Ltd | 3.5 Million USD | -72.589% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -8937.936% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 87.966% |
| BioStem Technologies, Inc. | 15.9 Million USD | 61.967% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -1201.703% |
| LadRx Corporation | 2.2 Million USD | -174.889% |
| Cell Source, Inc. | 15.8 Million USD | 61.731% |
| Regen BioPharma, Inc. | 5.45 Million USD | -10.836% |
| Regen BioPharma, Inc. | 5.45 Million USD | -10.836% |
| NovAccess Global Inc. | 7.86 Million USD | 23.048% |
| Affymax, Inc. | 8.87 Million USD | 31.812% |
| Itoco Inc. | 1.65 Million USD | -265.907% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -194.848% |
| Mobile Lads Corp. | 1.31 Million USD | -360.526% |
| CytoDyn Inc. | 127.89 Million USD | 95.27% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -14371.638% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -286.178% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | 45.235% |
| SYBLEU INC | 681.41 Thousand USD | -787.714% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | 0.867% |
| International Stem Cell Corporation | 5.27 Million USD | -14.63% |
| Bioxytran, Inc. | 3.24 Million USD | -86.152% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -866.589% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | -31.012% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 85.245% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 72.832% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -198.659% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | -10.424% |
| Neutra Corp. | 973.52 Thousand USD | -521.348% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 79.152% |
| PureTech Health plc | 125.58 Million USD | 95.183% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -61.001% |
| IXICO plc | 1.9 Million USD | -218.32% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 70.534% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 94.146% |
| CSL Limited | 18.62 Billion USD | 99.968% |
| Cellectis S.A. | 249.36 Million USD | 97.574% |